We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Discovery of Rogue Protein Paves Way for Diagnostic Test to Detect Early-Onset Dementia

By LabMedica International staff writers
Posted on 08 Dec 2023

Neurodegenerative disorders are often marked by the buildup of amyloid filament inclusions of specific proteins in the brain. More...

These proteins are critical in diagnosing and treating the associated diseases. Frontotemporal lobar degeneration (FTLD) is one such disorder, leading to frontotemporal dementia, which ranks just behind Alzheimer's disease in prevalence. In about 10% of FTLD cases, the identity of the filament-forming protein was previously unknown. The protein FUS was the suspected culprit, given its presence in brain inclusions and its known genetic role in some instances of amyotrophic lateral sclerosis, another neurodegenerative condition. Now, researchers using electron cryo-microscopy have unexpectedly found that the filaments are instead formed by the protein TAF15.

The research team from MRC Laboratory of Molecular Biology (Cambridge, UK) extracted amyloid filaments from the brains of four individuals affected by this type of FTLD. They carried out neuropathological examinations on the brain tissues obtained. Employing electron cryo-microscopy, they identified a consistent amyloid filament structure across all samples. The advanced resolution of this technique allowed for the direct sequencing of the protein responsible for forming these filaments. Contrary to expectations, the protein identified was not FUS, but TAF15, a member of the same protein family.

This discovery is pivotal in understanding the molecular pathology of this type of FTLD. It marks the rare identification of a new protein within the limited group known to form amyloid filaments associated with neurodegenerative diseases. This group already includes well-known proteins such as amyloid-beta, tau, TDP-43, and alpha-synuclein. The revelation of TAF15 as the filament-forming protein in these cases of FTLD paves the way for new diagnostic and therapeutic approaches targeting this specific neurodegenerative disease.

Related Links:
MRC LMB


New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Gold Member
Aspiration System
VACUSAFE
New
Automatic CLIA Analyzer
Shine i6000
New
Pipette Calibration System
Artel PCS®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Plasma pTau217 testing can predict future amyloid accumulation and cognitive decline in cognitively healthy older adults (photo courtesy of Shutterstock)

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more

Industry

view channel
Image: Pathlight combines WGS and dPCR to identify and longitudinally track large‑scale genomic changes, known as structural variants (photo courtesy of SAGA Diagnositcs)

Roche Affiliate Expands MRD Portfolio with SAGA Acquisition

Foundation Medicine, Inc., an independent affiliate of Roche, announced plans to expand its monitoring portfolio with SAGA Diagnostics’ Pathlight, a personalized, tumor-informed molecular residual disease... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.